The House Energy and Commerce Subcommittee on Health held a legislative hearing yesterday, entitled, Cannabis Policies for the New Decade, to examine federal cannabis policy, including the implications of rescheduling cannabis to a less restrictive category and the potential of cannabis research.
More that 35 bipartisan representatives and key witnesses from the National Institute on Drug Abuse, the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) testified on current cannabis policy, the health effects of cannabis, and what steps Congress can take to allow for more research of cannabis products and compounds.
